about
Measurement of blood-brain barrier permeability in acute ischemic stroke using standard first-pass perfusion CT dataThe effect of ageing on human lymphocyte subsets: comparison of males and femalesImpulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field.A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia.Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson's DiseaseAssessment methods and factors associated with depression in Parkinson's disease.Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review.The clinical spectrum of anxiety in Parkinson's disease.Modulation of N400 in chronic non-fluent aphasia using low frequency Repetitive Transcranial Magnetic Stimulation (rTMS).N400 and emotional word processing in Parkinson's disease.Practical approaches to commencing device-assisted therapies for Parkinson's disease in Australia.Guidelines for filming digital camera video clips for the assessment of gait and movement disorders by teleneurology.Factors associated with depression in Parkinson's disease.The time course and determinants of blood pressure within the first 48 h after ischemic stroke.The effect of admission physiological variables on 30 day outcome after stroke.The time course and determinants of temperature within the first 48 h after ischaemic stroke.Apomorphine-induced penile erections in Parkinson's disease.Apomorphine as an alternative to sildenafil in Parkinson's disease.Vertebrobasilar dissections: case series comparing patients with and without dissecting aneurysms.Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?'North Sea' progressive myoclonus epilepsy: phenotype of subjects with GOSR2 mutation.Management of impulse control disorders in Parkinson's disease.Risk factors for idiopathic dystonia in Queensland, Australia.Unilateral pallidotomy for Parkinson's disease disrupts ocular fixation.Stepwise partitioning of Xp21: a profiling method for XK deletions causative of the McLeod syndrome.Bilaterally coherent tremor resembling enhanced physiological tremor: report of three cases.Congenital disorder of glycosylation type Ia presenting as early-onset cerebellar ataxia in an adult.Improved receptive and expressive language abilities in nonfluent aphasic stroke patients after application of rTMS: an open protocol case series.Validity and reliability of the Geriatric Anxiety Inventory in Parkinson's disease.Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease.Stimulating debate in the field of addiction.Haplotype analysis of the PARK 11 gene, GIGYF2, in sporadic Parkinson's disease.Ring enhancement after hemorrhagic stroke.First case report of X linked dystonia parkinsonism (XDP) or 'lubag' in Australia.The effects of low frequency Repetitive Transcranial Magnetic Stimulation (rTMS) and sham condition rTMS on behavioural language in chronic non-fluent aphasia: Short term outcomes.Impact of Premorbid Undernutrition on Outcome in Stroke PatientsAltered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosisMotor imagery in Parkinson's disease: A PET studyLevels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke
P50
Q30687559-666D3B9F-BEE9-45E9-AC0A-853B9C12949BQ33804295-F776B4FD-1983-4156-B938-18C0D1AF79FDQ34153491-85E83EB9-F4D8-4263-A133-FFCA566F5CACQ35136950-F48605BB-FF12-465E-A910-C96E6262B0A0Q36828259-0B4612C9-ACE2-4C5D-86A0-C475633ADC8FQ37901875-B9E7BC93-B036-499A-97BF-63B43BC9D91BQ37906769-0BDD97C9-287E-475F-959D-03A6C7244A41Q37911815-76EBCE44-40A1-482C-B5D4-72ACD9376026Q38231914-6093E3AF-BD22-489F-A9BA-B34C3D083D88Q38371509-9395ECE6-6806-4E7C-9512-FCADE295E7DFQ38379525-A94F29F4-A349-43A4-AF2E-082368215696Q39134831-BE6A329B-AB2F-462D-BA1E-C6AB720AFB9EQ39733835-006C3F85-6B30-4509-A00E-C4C22BC7DC4AQ39778033-12845D24-C474-496F-8984-B865A35C31F9Q40172768-C5D045D2-D1D6-48A8-A268-9A5F46F212CFQ40376707-2A717825-FD70-476E-8BE4-62D2061024D6Q40449273-556001A3-3A5D-448A-86F3-FCB5EEEC99F8Q42541986-11B54076-A4E0-438B-9B86-0999E92A9443Q43070167-BEBBCCDE-0C9B-4DFC-BDF6-71EB15806817Q44083301-38F82A14-3C3A-4662-B0DA-BFCD13FC2CE5Q46118551-917E4FD4-A885-47AB-B673-8C1127457884Q46732385-55E187A3-BD48-4614-81CE-08426161D4E2Q48177158-CA79CEFF-3B84-4EB5-A866-0D9A8DA4B445Q48242406-AC532476-730E-4D99-97E5-4502A85FCABEQ48364926-BAABB41B-A71B-4A07-A9D9-6D1D5A991D84Q48642508-55557957-6807-4A31-B366-64A58E7F752BQ48647322-75CEDC25-AE10-4CBA-B0FF-DFF82B043658Q48647928-8C749299-3A33-4F82-90FD-D1B4A4D7BEDCQ48807841-676DD6E4-CEBE-404E-B83B-32243E4A9E44Q50586490-F409AF62-90B3-4494-8AE1-44E12A8E351DQ50984233-2993A0A6-0C6C-4A0D-8295-F455A69A242AQ52300123-E658E6FA-D592-4298-8CD2-26461B592962Q53519948-308929F1-DE27-462D-9E22-6B0C6618B1EEQ53604627-371CAA4D-56F5-4B8B-A95C-2637CF1885DAQ54634716-80ADD522-92F5-4EB5-A38F-19109F91D607Q54650064-E76BE55C-62F0-4594-8830-CCE2E8FE3AD9Q57198157-E0005425-91E9-4168-91EA-092539FA3A2DQ60324733-103C96F1-6653-453D-854F-6F1195869949Q61606600-C3EC6FB1-DF17-4A1A-BF78-B1523628EE5FQ63535271-C892049B-6DFF-4B1E-8509-3EC18A984D78
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John O'Sullivan
@ast
John O'Sullivan
@en
John O'Sullivan
@es
John O'Sullivan
@nl
John O'Sullivan
@sl
type
label
John O'Sullivan
@ast
John O'Sullivan
@en
John O'Sullivan
@es
John O'Sullivan
@nl
John O'Sullivan
@sl
prefLabel
John O'Sullivan
@ast
John O'Sullivan
@en
John O'Sullivan
@es
John O'Sullivan
@nl
John O'Sullivan
@sl
P106
P1153
7201881341
P31
P496
0000-0003-0422-8590